DivestmentJul 7, 2026, 04:33 PM
MacroGenics Completes $122.5M Sale of Manufacturing Ops to Bora
AI Summary
MacroGenics, Inc. announced the completion of the previously disclosed sale of its GMP manufacturing operations, including its CDMO business, to Bora Pharmaceuticals Co., Ltd. The transaction, effective June 30, 2026, generated $122.5 million in gross proceeds for MacroGenics. As part of the deal, approximately 140 employees transferred to Bora, and MacroGenics entered into a supply agreement with Bora for its internal pipeline needs, streamlining its focus on biopharmaceutical development.
Key Highlights
- MacroGenics completed the sale of its GMP manufacturing operations to Bora Pharmaceuticals.
- The transaction was effective as of June 30, 2026.
- Bora Pharmaceuticals paid MacroGenics $122.5 million before transaction fees and expenses.
- Approximately 140 former MacroGenics employees transferred to Bora.
- MacroGenics entered into a supply agreement with Bora for process development and drug substance production.
- The transaction resulted in an estimated gain on derecognition of Purchased Assets of $106.1 million.
- Pro forma cash and cash equivalents increased by $110.7 million due to the sale proceeds.
Price Impact
More from MGNX